Antiangiogenic Therapy With Pioglitazone, Rofecoxib, and Trofosfamide in a Patient With Endemic Kaposi Sarcoma

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

2000 • 1,536 citations

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

2000 • 1,159 citations

PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs

1999 • 1,091 citations

Kaposi's Sarcoma

2000 • 989 citations

Differentiation and reversal of malignant changes in colon cancer through PPARγ

1998 • 984 citations

Idiopathisches multiples Pigmentsarkom der Haut

1872 • 877 citations

The contributions of cyclooxygenase-2 to tumor angiogenesis.

2000 • 363 citations

PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

2002 • 352 citations

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors

2003 • 145 citations

Kaposi's sarcoma

1992 • 92 citations

Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II

2001 • 77 citations

Indocyanine green and laser light for the treatment of AIDS-associated cutaneous Kaposi's sarcoma

1998 • 75 citations

Approach to angiogenesis inhibition based on cyclooxygenase-2.

2002 • 55 citations

Treatment of Kaposiʼs sarcoma—an update

2002 • 34 citations

Trofosfamide

1997 • 21 citations

Kaposi’s sarcoma

2001 • 17 citations